Study of Stereotactic Ablative Radiotherapy (SABR) in Elderly Stage I NSCLC

Phase II Study of Stereotactic Ablative Radiotherapy in Elderly Patients With Stage I Non-Small Cell Lung Cancer

This study aims to prospectively investigate the efficacy, toxicity and quality of life (QOF) of stereotactic ablative radiotherapy (SABR) using a moderate fractionation of 72 Gy/6 Gy/12 F (BED10 = 115 Gy) in a single arm of elderly ( ≥ 70) patients with stage I (2009 UICC) non-small cell lung cancer (NSCLC).

This study aims to prospectively investigate the local regional control, overall survival, treatment related toxicities and quality of life (QOF) of elderly stage I NSCLC patients receiving stereotactic ablative radiotherapy (SABR) with a moderate fractionation of 72 Gy/6 Gy/12 F (BED10 = 115 Gy). Patients' general characteristics, treatment modality, dose-volume histogram (DVH) parameters, toxicity profiling, quality of life, pattern of failure as well as survival time will be prospective recorded for the analysis.

Inclusion Criteria:

• Age ≥ 70
• Pathologically or cytologically confirmed NSCLC
• Stage T1- 2 N0M0 based on adequate workup
• Peripheral tumor
• Eastern Cooperative Oncology Group (ECOG) 0-1
• Inoperable NSCLC

Exclusion Criteria:

• Pathologically or cytologically confirmed SCLC
• Direct evidence of regional or distant metastasis
• Central tumor
• Past history of malignancy
• Past history of thoracic irradiation
• Past history of chemotherapy
• Past history of thoracic surgery
• Pure Bronchioalveolar adenocarcinoma
• Active systemic, pulmonary or pleural lung diseases
• Pulmonary infection